Cero Therapeutics Holdings, Inc.
CERO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001870404
No open-market purchases or sales by Cero Therapeutics Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCEROW
13F holders, Q1 2025
Institutional positions in Cero Therapeutics Holdings, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- −6 vs. Q4 2024
- Shares held
- 723.1K
- −12.6M (−94.6%) vs. Q4 2024
- Total value
- $527.7K
- −$272.6K (−34.1%) vs. Q4 2024
- New holders
- 7
- 0 more added
- Sold out
- 13
- 8 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CERO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 11 | $798.7K |
| Q2 2025 | 8 | $2.38M |
| Q1 2025 | 15 | $527.7K |
| Q4 2024 | 21 | $800.3K |
| Q3 2024 | 18 | $320.0K |
| Q2 2024 | 15 | $557.1K |
| Q1 2024 | 9 | $4.85M |
| Q4 2023 | 10 | $7.49M |
| Q3 2023 | 10 | $7.33M |
| Q2 2023 | 13 | $10.6M |
| Q1 2023 | 17 | $12.5M |
| Q4 2022 | 46 | $101.1M |
| Q3 2022 | 66 | $153.0M |
| Q2 2022 | 54 | $144.5M |
| Q1 2022 | 45 | $137.2M |
| Q4 2021 | 36 | $104.2M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Cero Therapeutics Holdings, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FNY Investment Advisers, LLC | 262 | $0 | 0.00% | −25,988−99.0% | Reduced |
| JPMorgan Chase & Co | 1 | $1 | 0.00% | −139−99.3% | Reduced |
| Advisor Group Holdings, Inc. | 4 | $2 | 0.00% | −396−99.0% | Reduced |
| Bank of America Corp | 18 | $13 | 0.00% | −667−97.4% | Reduced |
| Barclays PLC | 102 | $74 | 0.00% | +102 | New |
| SBI Securities Co., Ltd. | 110 | $80 | 0.00% | −5,413−98.0% | Reduced |
| Tower Research Capital LLC (TRC) | 5,018 | $3.66K | 0.00% | −68,652−93.2% | Reduced |
| Susquehanna International Group, LLP | 13,343 | $9.74K | 0.00% | +13,343 | New |
| Citadel Advisors LLC | 16,218 | $11.8K | 0.00% | +16,218 | New |
| Geode Capital Management, LLC | 16,917 | $12.3K | 0.00% | +16,917 | New |
| ARCH Venture Management, LLC | 22,102 | $16.1K | 0.01% | −9,371,459−99.8% | Reduced |
| UBS Group AG | 42,687 | $31.2K | 0.00% | +42,687 | New |
| Avantax Planning Partners, Inc. | 74,321 | $54.3K | 0.00% | −2,510,830−97.1% | Reduced |
| Parallel Advisors, LLC | 220,000 | $160.6K | 0.00% | +220,000 | New |
| Armistice Capital, LLC | 312,000 | $227.8K | 0.01% | +312,000 | New |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −333,442−100.0% | Sold out |
| JustInvest LLC | 0 | $0 | 0.00% | −234,657−100.0% | Sold out |
| Cantor Fitzgerald, L. P. | 0 | $0 | 0.00% | −155,000−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −162,474−100.0% | Sold out |
| Selkirk Management LLC | 0 | $0 | 0.00% | −121,040−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −63,054−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −57,459−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −25,752−100.0% | Sold out |
| Revolve Wealth Partners, LLC | 0 | $0 | 0.00% | −32,799−100.0% | Sold out |
| HBK Sorce Advisory LLC | 0 | $0 | 0.00% | −26,249−100.0% | Sold out |
| Guidance Point Advisors, LLC | 0 | $0 | 0.00% | −18,717−100.0% | Sold out |
| Marex Group plc | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Birchview Capital, LP | 0 | $0 | 0.00% | −12,972−100.0% | Sold out |